November 2015 — CLASSIFICATION of sarcomas by looking at the tumor cells under the microscope has revealed different kinds of soft tissue sarcomas that show similarities. Laboratory methods have been able to pinpoint high-grade forms of Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, and other sarcoma subtypes. There are more than 50 sarcoma subtypes.
Researchers continue to progress in studies involving DNA and changes in DNA of soft tissue cells that cause sarcomas. Such studies have contributed to accurate sarcoma classifications. Studying normal and malignant soft tissue cells will hopefully lead to more new strategies for the advancement of treatment options.
TARGETED DRUG RESEARCH and chemotherapy research continues. Finding drugs to block the molecules in tumor cells that cause proliferation/growth/recurrence has been the ongoing. TRABECTEDIN recently was approved by the FDA for use in the United States, which is good news for Leiomyosarcoma and Liposarcoma patients.
ANTI-ANGIOGENESIS DRUGS block new blood vessels from forming, and may help eliminate sarcoma tumor cell growth by preventing their ability to use blood vessels to their advantage.
Some patients have been given AVASTIN with DOXORUBICIN (Adriamycin). Cediranib is another new anti-angiogenesis drug that is showing potential for certain types of soft tissue sarcomas.
Oncology Researchers are working hard and the evidence is always presented at annual Connective Tissue Oncology Society (CTOS) and American Society of Clinical Oncology (ASCO) conferences. They are our Champions of Hope.
Being informed patients allows empowerment – by being able to ask good / specific questions during appointments with your oncologist . You are being a self-advocate. It is important to learn as much as you can about your sarcoma sub-type.
Talk to your oncologist to get more information and answers to your questions.
The National Leiomyosarcoma Foundation only offers information on research articles and does not provide medical advice to patients.
Reaching For the Cure Together